Increased Levels of Circulating Islet Amyloid Polypeptide in Patients with Chronic Renal Failure Have No Effect on Insulin Secretion

作者: B Ludvik , M Clodi , A Kautzky-Willer , M Schuller , H Graf

DOI: 10.1172/JCI117558

关键词:

摘要: To elucidate the metabolism of islet amyloid polypeptide (IAPP) with respect to a possible renal elimination we investigated IAPP levels in 20 lean, nondiabetic patients failure maintained on chronic hemodialysis (HD) and healthy controls. The basal were significantly higher uremic than controls (15.1 +/- 3.2 vs. 0.2 pM, P < 0.001) suggesting excretion IAPP. investigate impact chronically elevated endogenous insulin secretion sensitivity, frequently sampled intravenous glucose tolerance test (FSIGT) was performed subset age-matched (C) obese normal (NGT) impaired (IGT). Insulin sensitivity index (SI) 8.7 1.5 C (P 0.05 NGT, 0.01 IGT), 5.4 0.9 HD 3.1 1.0 2.0 0.5 IGT. First phase increased compared those several control groups. results this study therefore indicate route Increased circulating over long period time do not lead decrease release cause resistance commonly seen obesity diabetes. are likely be pathogenetic factor development non-insulin-dependent diabetes mellitus (NIDDM).

参考文章(25)
Per Westermark, Christer Wernstedt, Erik Wilander, Knut Sletten, A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas Biochemical and Biophysical Research Communications. ,vol. 140, pp. 827- 831 ,(1986) , 10.1016/0006-291X(86)90708-4
R Prager, P Wallace, J M Olefsky, In vivo kinetics of insulin action on peripheral glucose disposal and hepatic glucose output in normal and obese subjects. Journal of Clinical Investigation. ,vol. 78, pp. 472- 481 ,(1986) , 10.1172/JCI112599
A. Lukinius, E. Wilander, G. T. Westermark, U. Engstr�m, P. Westermark, Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia. ,vol. 32, pp. 240- 244 ,(1989) , 10.1007/BF00285291
G. J. Cooper, B. Leighton, G. D. Dimitriadis, M. Parry-Billings, J. M. Kowalchuk, K. Howland, J. B. Rothbard, A. C. Willis, K. B. Reid, Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle Proceedings of the National Academy of Sciences of the United States of America. ,vol. 85, pp. 7763- 7766 ,(1988) , 10.1073/PNAS.85.20.7763
E. Hartter, T. Svoboda, B. Ludvik, M. Schuller, B. Lell, E. Kuenburg, M. Brunnbauer, W. Woloszczuk, R. Prager, Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia. ,vol. 34, pp. 52- 54 ,(1991) , 10.1007/BF00404025
H. Ohsawa, A. Kanatsuka, T. Yamaguchi, H. Makino, S. Yoshida, Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets Biochemical and Biophysical Research Communications. ,vol. 160, pp. 961- 967 ,(1989) , 10.1016/0006-291X(89)92529-1
G. J. Cooper, A. C. Willis, A. Clark, R. C. Turner, R. B. Sim, K. B. Reid, Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients Proceedings of the National Academy of Sciences of the United States of America. ,vol. 84, pp. 8628- 8632 ,(1987) , 10.1073/PNAS.84.23.8628
T. Sanke, T. Hanabusa, Y. Nakano, C. Oki, K. Okai, S. Nishimura, M. Kondo, K. Nanjo, Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. ,vol. 34, pp. 129- 132 ,(1991) , 10.1007/BF00500385